Key facts
- This page summarizes Julie B. Feder's Form 4 filing for Aura Biosciences, Inc. (AURA).
- 7 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 21 Oct 2024, 18:23.
Julie B. Feder - 18 Oct 2024 Form 4 Insider Report for Aura Biosciences, Inc. (AURA)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- AURA
- Reported as of
- 18 Oct 2024
- Net transaction value
- -$215,829
- SEC form
- 4
- Accepted by SEC
- 21 Oct 2024, 18:23:22 UTC
- Prior SEC filing
- 02 Feb 2024
- Next SEC filing
- 03 Aug 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Conor Kilroy, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Julie B. Feder filed Form 4 for Aura Biosciences, Inc. (AURA) on 21 Oct 2024.
Change
- Previous filing in this sequence was filed on 02 Feb 2024.
- Current net transaction value: -$215,829.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AURA
transaction
Common Stock
Options Exercise
- Transaction value
- $47,950
- Shares
- +17,500
- Change %
- +13%
- Price
- $2.74
- Shares after
- 151,776
- Date
- 18 Oct 2024
- Ownership
- Direct
- Footnotes
- F1
AURA
transaction
Common Stock
Options Exercise
- Transaction value
- $11,182
- Shares
- +2,631
- Change %
- +1.7%
- Price
- $4.25
- Shares after
- 154,407
- Date
- 18 Oct 2024
- Ownership
- Direct
- Footnotes
- F1
AURA
transaction
Common Stock
Options Exercise
- Transaction value
- $27,400
- Shares
- +5,000
- Change %
- +3.2%
- Price
- $5.48
- Shares after
- 159,407
- Date
- 18 Oct 2024
- Ownership
- Direct
- Footnotes
- F1
AURA
transaction
Common Stock
Sale
- Transaction value
- $302,361
- Shares
- -25,131
- Change %
- -16%
- Price
- $12.03
- Shares after
- 134,276
- Date
- 18 Oct 2024
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AURA
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -17,500
- Change %
- -20%
- Price
- $0.000000
- Shares after
- 68,257
- Date
- 18 Oct 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 17,500
- Exercise price
- $2.74
- Footnotes
- F1, F3
AURA
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -2,631
- Change %
- -7.5%
- Price
- $0.000000
- Shares after
- 32,359
- Date
- 18 Oct 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,631
- Exercise price
- $4.25
- Footnotes
- F1, F3
AURA
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -5,000
- Change %
- -4%
- Price
- $0.000000
- Shares after
- 120,547
- Date
- 18 Oct 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,000
- Exercise price
- $5.48
- Footnotes
- F1, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 23, 2023 previously adopted by the reporting person.
Footnote F2
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.0000 to $12.3000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F3
This option is fully vested.
Footnote F4
The shares underlying this option vest in 48 monthly installments, equal to 2.0833% of the shares, over the 48 months following June 28, 2021.
SEC remarks
Exhibit 24.1 - Power of Attorney